Read More

CareDx Responds To Natera’s Filing Of A Motion For An Injunction Related To Patent 11,111,544; CareDx Informed Natera And The Court, Since August 2023, CareDx Has Utilized A New Allosure Process That It Believes Does Not Infringe On The ‘544 Patent.

CareDx Reiterates Position that it Does Not Infringe Natera's ‘544 PatentInjunction Motion has No Impact on CareDx's Business or Patient and Clinician Access to AlloSure or AlloMapCareDx, Inc. (NASDAQ:CDNA) – The

CDNA

Read More

Windward Management Issues Letter To NETGEAR Board Advising The Immediate Repurchase Of At Least 25% Of The Shares Outstanding, ~$100M, & the Formation Of A Strategic Review Committee To Examine Splitting Off And/Or Selling The NFB Segment

Current net cash is equal to ~80% of NETGEAR's market cap & recent company-provided 2024 free cash flow guidance implies a de minimis, to potentially negative, enterprise value by year-endWindward believes splitting

NTGR